nach oben

International Journal of Clinical Oncology

Erschienen in:

09.01.2020 | Invited Review Article

Immune-resistant mechanisms in cancer immunotherapy

verfasst von: Yutaka Kawakami, Shigeki Ohta, Mohammad A. Sayem, Nobuo Tsukamoto, Tomonori Yaguchi

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Immune checkpoint inhibitors (ICI) such as PD-1/PD-L1 antibodies (Abs) and CTLA4 Abs and T cell-based adoptive cell therapies are effective for patients with various cancers. However, response rates of ICI monotherapies are still limited due to lack of immunogenic antigens and various immune-resistant mechanisms. The latter includes adaptive immune resistance that is caused by anti-tumor T cells (e.g. PD-L1 induced by IFN-γ from T cells) and primary immune resistance that is caused by cancer cells (e.g. immunosuppressive cytokines produced by cancer cells). Further understanding of the immune-resistant mechanisms, which may be possible through comparative analyses of responders and non-responders to the immunotherapies, will lead to the identification of new diagnostic biomarkers and therapeutic targets for development of effective cancer immuno therapies.

Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer immunotherapy. Science 342:1432–1433PubMedCrossRef

Iwai Y, Ishida M, Tanaka Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293–12297PubMedPubMedCentralCrossRef

Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443PubMedPubMedCentralCrossRef

Okazaki T, Chikuma S, Iwai Y et al (2013) Rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14:1212–1218PubMedCrossRef

Yaguchi T, Kawakami Y (2016) Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int Immunol 28:393–399PubMedPubMedCentralCrossRef

Kawakami Y, Fujita T, Matsuzaki Y et al (2004) Identification of human tumor antigens and its implication for diagnosis and treatment of cancer. Cancer Sci 95:784–791PubMedCrossRef

Robbins PF, Lu YC, El-Gamil M et al (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747–752PubMedPubMedCentralCrossRef

Coulie PG, Van den Eynde BJ, van der Bruggen P et al (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14:135–146PubMedCrossRef

Taube JM, Anders RA, Young GD et al (2014) Colocalization of inflammatory response with B7–h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127

10.

Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571PubMedPubMedCentralCrossRef

11.

Spranger S, Spaapen RM, Zha Y et al (2013) Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 5:200CrossRef

12.

Sade-Feldman M, Yizhak K, Bjorgaard SL et al (2018) Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175:998–1013PubMedPubMedCentralCrossRef

13.

Huang AC, Postow MA, Orlowski RJ et al (2017) T cellinvigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60PubMedPubMedCentralCrossRef

14.

Topalian SL, Drake CG et al (2015) lImmune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450–461PubMedPubMedCentralCrossRef

15.

Neubert NJ, Schmittnaegel M, Bordry N et al (2018) T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Sci Transl Med 10:436CrossRef

16.

Kinoshita T, Kudo-Saito C, Muramatsu R et al (2017) Determination of poor prognostic immune features of tumor microenvironment in nonsmoking patients with lung adenocarcinoma. Eur J Cancer 86:15–27PubMedCrossRef

17.

Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133PubMedPubMedCentralCrossRef

18.

Arce F, Furness AJS, Solomon I et al (2017) Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory t cells and synergizes with pd-1 blockade to eradicate established tumors. Immunity 46:577CrossRef

19.

Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1PubMedCrossRef

20.

Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541:321PubMedCrossRef

21.

Hellmann MD, Snyder A et al (2015) Cancer immunology mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128PubMedPubMedCentralCrossRef

22.

Alexandrov LB, Nik-Zainal S, Wedge DC et al (2013) Signatures of mutational processes in human cancer. Nature 500:415–421PubMedPubMedCentralCrossRef

23.

Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523:231PubMedCrossRef

24.

Mlecnik B, Bindea G, Angell HK et al (2014) Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med 6:228CrossRef

25.

Zitvogel L, Kepp O, Kroemer G et al (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151–160PubMedCrossRef

26.

Spranger S, Luke JJ, Bao R et al (2016) Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci USA 113:7759–7768CrossRef

27.

Peng W, Chen JQ, Liu C et al (2016) Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6:202PubMedCrossRef

28.

Yaguchi T, Goto Y, Kido K et al (2012) Immune suppression and resistance mediated by constitutive activation of Wnt/ beta-catenin signaling in human melanoma cells. J Immunol 189:2110PubMedCrossRef

29.

Spranger S, Dai D, Horton B et al (2017) Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31:711PubMedPubMedCentralCrossRef

30.

Toda M, Iizuka Y, Kawase T et al (2002) Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Ther 9:356–364PubMedCrossRef

31.

Udagawa M, Kudo-Saito C, Hasegawa G et al (2006) Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin Cell Wall Skeleton Simulation. Clin Cancer Res 12:7465–7475PubMedCrossRef

32.

Osawa Y, Kojika E, Nishikawa K et al (2019) PD-L1 blockade attenuates the growth of metastatic colon cancer in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers. Oncotarget 10:3013–3026PubMedPubMedCentralCrossRef

33.

Robertson GP, Herbst RA, Nagane M et al (1999) The chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci. Cancer Res 59:3596–3601PubMed

34.

Voron T, Colussi O, Marcheteau E et al (2015) VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 212:139PubMedPubMedCentralCrossRef

35.

Yuan J, Zhou J, Dong Z et al (2014) Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2:127PubMedCrossRef

36.

Hodi FS, Lawrence D, Lezcano C et al (2014) Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2:632PubMedPubMedCentralCrossRef

37.

Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-Line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288–2301PubMedCrossRef

38.

Sumimoto H, Miyagishi M, Miyoshi H et al (2004) Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23:6031–6039PubMedCrossRef

39.

Hugo W, Shi H, Sun L et al (2015) Non-genomic and immune evolution of melanoma acquiring MAPKi Resistance. Cell 162:1271–1285PubMedPubMedCentralCrossRef

40.

Sumimoto H, Imabayashi F, Iwata T et al (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651PubMedPubMedCentralCrossRef

41.

Iwata-Kajihara T, Sumimoto H, Kawamura N et al (2011) Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J Immunol 187:27PubMedCrossRef

42.

Poulikakos PI, Zhang C, Bollag G et al (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427–430PubMedPubMedCentralCrossRef

43.

Cooper ZA, Reuben A, Amaria RN, Wargo JA (2014) Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. Oncoimmunology 3:e954956PubMedPubMedCentralCrossRef

44.

Wilmott JS, Long GV, Howle JR et al (2012) Selective BRAF inhibitors induce marked T cellinfiltration into human metastatic melanoma. Clin Cancer Res 18:1386PubMedCrossRef

45.

Spranger S, Gajewski TF (2018) Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer 18:139PubMedPubMedCentralCrossRef

46.

Davoli T, Uno H, Wooten E et al (2017) Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355(6322):2017CrossRef

47.

Hugo W, Zaretsky JM, Sun L et al (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:35PubMedPubMedCentralCrossRef

48.

Nakamura S, Yaguchi T, Kawamura N et al (2014) TGF-beta1 in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression. J Immunother 37:63PubMedCrossRef

49.

Tauriello DVF, Palomo-Ponce S, Stork D et al (2018) TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554:538PubMedCrossRef

50.

Mariathasan S, Turley SJ, Nickles D et al (2018) TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544PubMedPubMedCentralCrossRef

51.

Kudo-Saito C, Shirako H, Takeuchi T et al (2009) Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15:195PubMedCrossRef

52.

Lan Y, Zhang D, Xu C et al (2018) Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med 10:424CrossRef

53.

Satoh K, Yachida S, Sugimoto M et al (2018) Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC. Proc Natl Acad Sci USA 114:7697

54.

Beckermann KE, Dudzinski SO, Rathmell JC (2017) Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine Growth Factor Rev 35:7PubMedPubMedCentralCrossRef

55.

Cascone T, McKenzie JA, Mbofung RM et al (2018) Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. Cell Metab 27:977PubMedPubMedCentralCrossRef

56.

Scharping NE, Menk AV, Moreci RS et al (2016) The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45:374–388PubMedPubMedCentralCrossRef

57.

Eikawa S, Nishida M, Mizukami S et al (2015) Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA 112:1809PubMedPubMedCentralCrossRef

58.

Kunisada Y, Eikawa S, Tomonobu N et al (2017) Attenuation of CD4⁺CD25⁺ regulatory T cells in the tumor microenvironment by metformin, a type 2 diabetes drug. EBioMedicine 25:154PubMedPubMedCentralCrossRef

59.

Chamoto K, Chowdhury PS, Kumar A et al (2017) Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci USA 114:761CrossRef

60.

Rath M, Müller I, Kropf P et al (2014) Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front Immunol 5:532PubMedPubMedCentralCrossRef

61.

Santoro SP, Wang LP et al (2014) Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 20:607–615PubMedPubMedCentralCrossRef

62.

Kidani Y, Bensinger S (2016) Modulating cholesterol homeostasis to build a better T cell. Cell Metab 23:963PubMedCrossRef

63.

Ohta A (2016) A metabolic immune checkpoint: adenosine in tumor microenvironment. Front Immunol 7:109PubMedPubMedCentralCrossRef

64.

Morello S, Capone M, Sorrentino C et al (2017) Soluble CD73 as Biomarker in patients with metastatic melanoma patients treated with Nivolumab. J Transl Med 15:244PubMedPubMedCentralCrossRef

65.

Chowell D, Morris LGT, Grigg CM et al (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359:582PubMedCrossRef

66.

Routy B, Le Chatelier E, Derosa L et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91PubMedCrossRef

67.

Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359:97PubMedCrossRef

68.

Matson V, Fessler J, Bao R et al (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359:104PubMedPubMedCentralCrossRef

69.

Tanoue T, Morita S, Plichta DR et al (2019) A defined consortium of human gut commensals induces CD8 T cells and modulates host microbial and cancer immunity. Nature 565:600–605PubMedCrossRef

70.

Derosa L, Hellmann MD, Spaziano M et al (2018) Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small cell lung cancer. Ann Oncol 29:1437–1444PubMedPubMedCentralCrossRef

71.

Wang Z, Aguilar EG, Luna JI et al (2019) Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med 25:141–151PubMedCrossRef

72.

Naik GS, Waikar S, Johns AEW et al (2019) Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer 7:89PubMedPubMedCentralCrossRef

73.

Zaretsky JM, Garcia-Diaz A, Shin DS et al (2016) Mutations associated with acquired resistance to pd-1 blockade in melanoma. N Engl J Med 375:819PubMedPubMedCentralCrossRef

74.

Restifo NP, Marincola FM, Kawakami Y et al (1996) Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100PubMedCrossRef

75.

Sade-Feldman M, Jiao YJ, Chen JH et al (2017) Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun 8:1136PubMedPubMedCentralCrossRef

76.

Gettinger S, Choi J, Hastings K et al (2017) Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov 7:1420PubMedPubMedCentralCrossRef

77.

Patel SJ, Sanjana NE, Kishton RJ et al (2017) Identification of essential genes for cancer immunotherapy. Nature 548:537PubMedPubMedCentralCrossRef

78.

Manguso RT, Pope HW, Zimmer MD et al (2017) In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547:413PubMedPubMedCentralCrossRef

Titel: Immune-resistant mechanisms in cancer immunotherapy
verfasst von: Yutaka Kawakami
Shigeki Ohta
Mohammad A. Sayem
Nobuo Tsukamoto
Tomonori Yaguchi
Publikationsdatum: 09.01.2020
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 5/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01611-x

Neu im Fachgebiet Onkologie

10.04.2024 | PSA-Screening | Nachrichten

Springer Medizin

Immune-resistant mechanisms in cancer immunotherapy

Abstract

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis

A message from the new editor-in-chief

Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology

Psoas muscle mass in patients undergoing lung cancer surgery: a prognostic difference between squamous cell carcinoma and adenocarcinoma

Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma

Laparoscopic versus abdominal radical hysterectomy for stage IB1 cervical cancer patients with tumor size ≤ 2 cm: a case-matched control study

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie